Get all premium features to the best stock analysis tool

CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.

CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.

Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CONMED Corporation (CNMD) Q4 2025 Earnings Call Transcript

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to dilute.